Equities

Talis Biomedical Corp

TLIS:NAQ

Talis Biomedical Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)9.20
  • Today's Change0.00 / 0.00%
  • Shares traded1.35k
  • 1 Year change+25.07%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.

  • Revenue in USD (TTM)989.00k
  • Net income in USD-57.21m
  • Incorporated2013
  • Employees99.00
  • Location
    Talis Biomedical Corp1100 Island Drive, Suite 101REDWOOD CITY 94065United StatesUSA
  • Phone+1 (650) 433-3000
  • Fax+1 (302) 636-5454
  • Websitehttps://talisbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cardio Diagnostics Holdings Inc33.00k-11.51m15.71m7.00--4.93--476.19-0.8257-0.82570.00210.14040.0051----4,714.29-178.70---325.81-------34,872.12-----4.840.0715--1,696.84---79.72------
Allied Corp21.51k-9.00m16.03m--------745.29-0.0915-0.09150.0002-0.07110.00511.650.1441---214.39-------6,919.57---41,861.41--0.0333-31.86-----56.46--31.30------
Galecto Inc0.00-30.83m16.48m13.00--0.5854-----1.15-1.150.001.040.00----0.00-63.50-48.46-78.33-52.36------------0.00------37.77------
Pharmacyte Biotech Inc0.00-14.82m16.57m2.00--0.5323-----1.64-1.640.005.740.00----0.00-1.53-13.35-1.62-13.70------------0.00-------1.81------
Talis Biomedical Corp989.00k-57.21m16.76m99.00--0.2958--16.95-31.44-31.440.543431.110.0092--14.879,989.90-53.08-68.18-58.71-74.2297.27---5,784.73-1,615.96----0.00---55.65-2.2445.13---1.83--
Nascent Biotech Inc0.00-2.09m16.80m----550.02-----0.0147-0.01470.000.00020.00-------346.80-815.53-----------548.75----0.8045---100.00---495.46------
Curative Biotechnology Inc0.00-6.02m17.16m4.00---------0.0105-0.01050.00-0.00180.00----0.00-339.98-----------------5.51---------302.92------
Kintara Therapeutics Inc0.00-9.51m17.17m2.00---------4.08-4.080.000.10710.00----0.00-131.55-220.94-185.60-329.97------------0.00------40.24--78.93--
Alaunos Therapeutics Inc6.00k-26.77m17.45m1.00--3.64--2,908.94-1.67-1.670.00040.29960.0002--12.006,000.00-97.94-74.83-147.22-89.57-----446,233.30-10,508.06---19.250.00---99.83-49.086.86---15.56--
GlycoMimetics Inc10.00k-37.28m17.47m35.00--0.6041--1,746.99-0.5791-0.57910.00020.44860.0002--0.0581285.71-72.29-43.60-81.84-47.82-----372,767.40-2,243.52----0.00---86.67--20.97---29.82--
Talphera Inc651.00k-14.31m17.50m15.00--1.07--26.89-0.8945-0.88630.03680.96120.0237----43,400.00-51.96-22.60-67.70-28.55-----2,197.39-714.87----0.00-----21.26-119.16---34.33--
Aytu Biopharma Inc93.76m-13.68m17.54m150.00--0.5699--0.1871-2.65-2.6518.215.530.67922.422.93625,053.30-9.91-33.56-25.58-52.8165.3256.89-14.60-73.810.69230.2160.352--11.1096.5684.33------
VBI Vaccines Inc9.41m-83.99m17.57m131.00------1.87-6.93-6.930.4818-0.21660.09231.4037.0571,839.70-81.40-46.58-171.57-58.62-24.06-277.46-881.79-2,755.980.2116-1.601.13--702.4020.9417.18---32.07--
Minerva Neurosciences Inc0.00-31.60m17.83m9.00---------4.48-4.480.00-5.230.00----0.00-61.90-49.89-65.32-52.39-------442.65------------6.55------
Data as of May 31 2024. Currency figures normalised to Talis Biomedical Corp's reporting currency: US Dollar USD

Institutional shareholders

51.59%Per cent of shares held by top holders
HolderShares% Held
Baker Bros. Advisors LPas of 31 Mar 2024508.32k27.95%
DME Capital Management LPas of 31 Mar 2024149.05k8.19%
Greenlight Capital, Inc.as of 31 Dec 2023149.05k8.19%
BML Capital Management LLCas of 31 Mar 202442.74k2.35%
The Vanguard Group, Inc.as of 31 Mar 202431.01k1.71%
Susquehanna Financial Group LLLPas of 31 Mar 202417.43k0.96%
Prelude Capital Management LLCas of 31 Mar 202414.93k0.82%
Geode Capital Management LLCas of 31 Mar 202411.89k0.65%
Renaissance Technologies LLCas of 31 Mar 202410.30k0.57%
Abaris Investment Management AGas of 30 Jun 20233.73k0.21%
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.